An Analysis of the Phase III ATLAS Trial in RCC​
Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
Thomas E. Hutson, DO, PharmD, medical oncologist, Texas OncologyBaylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
Clinical Pearls:
- The trial is currently in progress with over 100 patients enrolled.
- Researchers have seen very promising results with this class of agents in the metastatic setting, allowing patients with metastatic RCC to live years longer.
- Axitinib is the most potent VEGF inhibitor available, but it is the most narrow in terms of off-target effects. This may lead to greater tolerability in patients in the adjuvant setting.
- The hope is to treat patients who are at high risk of recurrence in the adjuvant setting with agents such as axitinib.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
